Amiri-Yekta Amir, Coutton Charles, Kherraf Zine-Eddine, Karaouzène Thomas, Le Tanno Pauline, Sanati Mohammad Hossein, Sabbaghian Marjan, Almadani Navid, Sadighi Gilani Mohammad Ali, Hosseini Seyedeh Hanieh, Bahrami Salahadin, Daneshipour Abbas, Bini Maurizio, Arnoult Christophe, Colombo Roberto, Gourabi Hamid, Ray Pierre F
Department of Genetics, Reproductive Biomedicine Research Center, Royan Institute for Reproductive Biomedicine, ACECR, PO Box 16635-148, Tehran, Iran.
Genetic Epigenetic and Therapies of Infertility, Institute for Advanced Biosciences, INSERM 1209, CNRS UMR 5309, Université Grenoble Alpes, Grenoble F38000, France.
Hum Reprod. 2016 Dec;31(12):2872-2880. doi: 10.1093/humrep/dew262. Epub 2016 Oct 26.
Can whole-exome sequencing (WES) of patients with multiple morphological abnormalities of the sperm flagella (MMAF) identify causal mutations in new genes or mutations in the previously identified dynein axonemal heavy chain 1 (DNAH1) gene?
WES for six families with men affected by MMAF syndrome allowed the identification of DNAH1 mutations in four affected men distributed in two out of the six families but no new candidate genes were identified.
Mutations in DNAH1, an axonemal inner dynein arm heavy chain gene, have been shown to be responsible for male infertility due to a characteristic form of asthenozoospermia called MMAF, defined by the presence in the ejaculate of spermatozoa with a mosaic of flagellar abnormalities including absent, coiled, bent, angulated, irregular and short flagella.
STUDY DESIGN, SIZE, DURATION: This was a retrospective genetics study of patients presenting a MMAF phenotype. Patients were recruited in Iran and Italy between 2008 and 2015.
PARTICIPANTS/MATERIALS, SETTING, METHODS: WES was performed for a total of 10 subjects. All identified variants were confirmed by Sanger sequencing. Two additional affected family members were analyzed by direct Sanger sequencing. To establish the prevalence of the DNAH1 mutation identified in an Iranian family, we carried out targeted sequencing on 38 additional MMAF patients of the same geographical origin. RT-PCR and immunochemistry were performed on sperm samples to assess the effect of the identified mutation on RNA and protein.
WES in six families identified a causal mutations in two families. Two additional affected family members were confirmed to hold the same homozygous mutation as their sibling. In total, DNAH1 mutations were identified in 5 out of 12 analyzed subjects (41.7%). If we only include index cases, we detected two mutated subjects out of six (33%) tested MMAF individuals. Furthermore we sequenced one DNAH1 exon found to be mutated (c.8626-1G > A) in an Iranian family in an additional 38 MMAF patients from Iran. One of these patients carried the variant confirming that this variant is relatively frequent in the Iranian population. The effect of the c.8626-1G > A variant was confirmed by RT-PCR and immunochemistry as no RNA or protein could be observed in sperm from the affected men.
N/A.
LIMITATIONS, REASONS FOR CAUTION: WES allows the amplification of 80-90% of all coding exons. It is possible that some DNAH1 exons may not have been sequenced and that we may have missed some additional mutations. Also, WES cannot identify deep intronic mutations and it is not efficient for detection of large genomic events (deletions, insertions, inversions). We did not identify any causal mutations in DNAH1 or in other candidate genes in four out of the six tested families. This indicates that the technique and/or the analysis of our data can be improved to increase the diagnosis efficiency.
Our findings confirm that DNAH1 is one of the main genes involved in MMAF syndrome. It is a large gene with 78 exons making it challenging and expensive to sequence using the traditional Sanger sequencing methods. We show that WES sequencing is good alternative to Sanger sequencing to reach a genetic diagnosis in patients with severe male infertility phenotypes.
STUDY FUNDING/COMPETING INTERESTS: This work was supported by following grants: the 'MAS-Flagella' project financed by the French ANR and the DGOS for the program PRTS 2014 and the 'Whole genome sequencing of patients with Flagellar Growth Defects (FGD)' project financed by the Fondation Maladies Rares for the program Séquençage à haut débit 2012. The authors have no conflict of interest.
对精子鞭毛多重形态异常(MMAF)患者进行全外显子组测序(WES)能否鉴定出新基因中的致病突变或先前已鉴定的动力蛋白轴丝重链1(DNAH1)基因中的突变?
对6个患有MMAF综合征男性的家庭进行WES,在6个家庭中的4名受影响男性中鉴定出DNAH1突变,这4名男性分布在其中2个家庭中,但未鉴定出新的候选基因。
轴丝内动力蛋白臂重链基因DNAH1中的突变已被证明是导致一种称为MMAF的弱精子症特征形式的男性不育的原因,MMAF的定义是射精中存在具有多种鞭毛异常的精子,包括无鞭毛、卷曲、弯曲、成角、不规则和短鞭毛。
研究设计、规模、持续时间:这是一项对呈现MMAF表型患者的回顾性遗传学研究。2008年至2015年间在伊朗和意大利招募患者。
参与者/材料、环境、方法:对总共10名受试者进行WES。所有鉴定出的变异均通过桑格测序确认。另外两名受影响的家庭成员通过直接桑格测序进行分析。为确定在一个伊朗家庭中鉴定出的DNAH1突变的患病率,我们对另外38名来自同一地理区域的MMAF患者进行了靶向测序。对精子样本进行逆转录聚合酶链反应(RT-PCR)和免疫化学分析,以评估鉴定出的突变对RNA和蛋白质的影响。
对6个家庭进行WES在2个家庭中鉴定出致病突变。另外两名受影响的家庭成员被确认与他们的兄弟姐妹持有相同的纯合突变。总共,在12名分析受试者中的5名(41.7%)中鉴定出DNAH1突变。如果仅包括索引病例,在6名接受检测的MMAF个体中有2名(33%)检测到突变。此外,我们对在一个伊朗家庭中发现发生突变(c.8626-1G>A)的一个DNAH1外显子,在另外38名来自伊朗的MMAF患者中进行了测序。其中一名患者携带该变异,证实该变异在伊朗人群中相对常见。RT-PCR和免疫化学证实了c.8626-1G>A变异的影响,因为在受影响男性的精子中未观察到RNA或蛋白质。
无。
局限性、谨慎原因:WES可扩增所有编码外显子的80-90%。可能某些DNAH1外显子未被测序,并且我们可能遗漏了一些其他突变。此外,WES无法鉴定内含子深处的突变,并且对于检测大的基因组事件(缺失、插入、倒位)效率不高。在6个测试家庭中的4个家庭中,我们未在DNAH1或其他候选基因中鉴定出任何致病突变。这表明该技术和/或我们的数据分析可以改进以提高诊断效率。
我们的研究结果证实DNAH1是参与MMAF综合征的主要基因之一。它是一个具有78个外显子的大基因,使用传统桑格测序方法进行测序具有挑战性且成本高昂。我们表明,WES测序是对患有严重男性不育表型患者进行基因诊断的替代桑格测序的良好方法。
研究资金/利益冲突:这项工作得到了以下资助:由法国国家研究机构(ANR)和法国卫生总署(DGOS)为2014年PRTS计划资助的“MAS-鞭毛”项目,以及由罕见病基金会为2012年高通量测序计划资助的“鞭毛生长缺陷(FGD)患者的全基因组测序”项目。作者没有利益冲突。